Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Urogenital Neoplasms 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Graft vs Host Disease 2Colitis 2Carcinoma, Non-Small-Cell Lung 2Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Crohn Disease 1Colitis, Ulcerative 1

Interventions

Cyclophosphamide 54Tacrolimus 50Methotrexate 36Mycophenolic Acid 34fludarabine phosphate 33Busulfan 31Cyclosporine 29fludarabine 28Antilymphocyte Serum 28Melphalan 23Sirolimus 21Whole-Body Irradiation 18Radiotherapy 18Peripheral Blood Stem Cell Transplantation 18Methylprednisolone 18Filgrastim 15thymoglobulin 13Thiotepa 10Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 8Hematopoietic Stem Cell Transplantation 7Etoposide 7Cord Blood Stem Cell Transplantation 7Cytarabine 6Alemtuzumab 6ruxolitinib 5Transplantation 5Therapeutics 5Prednisone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Graft vs Host Disease × vedolizumab × Clear all
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06475820 2024-08-23

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Active not recruiting
150 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡